Chr. Hansen is on track to execute on its 2025 strategy. Q1 2020/21 organic sales growth was 10 %, equally split between volume/mix and price, and driven by Health & Nutrition, which delivered 15 % growth, while Food Cultures & Enzymes delivered 8 % growth. Revenue rose from EUR 220 m in Q1 2019/20 to EUR 243.5 in Q1 2020/21.
The company reports an underlying Ebit margin b.s.i. of 28. 5 %, incl. 1 %-point negative currency impact, compared to 29.0 % in Q1 2019/20. Reported Ebit margin b.s.i. (incl. all acquisition impacts) was 25.2 %. The divestment process of Natural Colours is also on track and the business delivered as expected.
CEO Mauricio Graber says: “Our first quarter came in quite strong on a relatively easy comparable from Q1 last year, with good performance across our business, especially within Health & Nutrition. We were able to win new business, launch new products in Food Cultures & Enzymes and drive upselling in key markets such as cheese – all despite the difficulties of Covid-19. We have more product launches scheduled for the current financial year, which will help to ensure that we have a healthy commercial pipeline in the years to come.”